By Sabela Ojea
Applied Therapeutics said it has received a complete response letter from the Food and Drug Administration related to its new drug application for govorestat due to deficiencies in the clinical application.
Shares dropped 16% to $8.57 in post-marketing trading. Through Wednesday's close, the stock has more-than-doubled since the beginning of the year.
The FDA issues a complete response letter when it decides not to approve a new drug application in its present form.
The biopharmaceutical company on Wednesday said it is reviewing the feedback from the FDA and plans to immediately request a meeting to potentially resubmit the NDA for the treatment of galactosemia or appeal the decision along with appropriate next steps.
"We are disappointed by the FDA's decision today," Chief Executive Shoshana Shendelman said.
Galactosemia is a progressive and debilitating disease without any existing treatment options, the executive added.
Overall, Galactosemia a rare genetic disorder that prevents the body from processing galactose.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
November 27, 2024 16:33 ET (21:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。